I'm glad they have given up on cancer markers (I argued with JS last year they would be wasting time believing they could compete with Big Pharma).
IMO, the wine market is the place to be, but he doesn't seem to understand that. (Too much hard work? like actually going to Wineries??).
I don't know if the EU would have barriers (probably does) or the US market. But there should be a knowledge base at Rowville, deciding where to start with Sentia. And then acting.
Ann: FDA Approval for Xprecia Prime, page-114
Add UBI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.010(7.69%) |
Mkt cap ! $41.72M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.0¢ | 13.0¢ | $5.731K | 40.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 612543 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 187011 | 7 |
View Market Depth
| Last trade - 15.45pm 20/09/2024 (20 minute delay) ? |
| UBI (ASX) Chart |